(Q39159200)

9 September 2017

The discovery of setileuton, a potent and selective 5-lipoxygenase inhibitor (English)

1 reference

9 September 2017

Yves Ducharme

1

1 reference

9 September 2017

Marc Blouin

2

1 reference

9 September 2017

Christine Brideau

3

1 reference

9 September 2017

Anne Châteauneuf

4

1 reference

9 September 2017

Yves Gareau

5

1 reference

9 September 2017

Erich L Grimm

6

1 reference

9 September 2017

Hélène Juteau

7

1 reference

9 September 2017

Sébastien Laliberté

8

1 reference

9 September 2017

Bruce MacKay

9

1 reference

9 September 2017

Frédéric Massé

10

1 reference

9 September 2017

Marc Ouellet

11

1 reference

9 September 2017

Myriam Salem

12

1 reference

9 September 2017

Angela Styhler

13

1 reference

9 September 2017

Richard W Friesen

14

1 reference

9 September 2017

13 April 2010

1 reference

ACS Medicinal Chemistry Letters

9 September 2017

1 reference

9 September 2017

1

1 reference

9 September 2017

4

1 reference

9 September 2017

170-174

1 reference

Targeting leukotrienes for the treatment of COPD?

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Inhibitors of the 5-lipoxygenase pathway in atherosclerosis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

5-Lipoxygenase: regulation of expression and enzyme activity

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Medicinal chemistry of hERG optimizations: Highlights and hang-ups

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Therapeutic options for 5-lipoxygenase inhibitors

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Substituted coumarins as potent 5-lipoxygenase inhibitors

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007958

Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability

21 August 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo

1 reference

PubMed

12 December 2020

Leukotriene generation and metabolism in dogs: inhibition of biosynthesis by MK-0591

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1021/ML100029K

1 reference

9 September 2017

1 reference

9 September 2017

PubMed publication ID

24900191

1 reference